logo

For the Inventor, By the Inventor

London, United Kingdom

Cancer Research Technology Limited


USPTO Granted Patents = 263



Trademarks = 3

Forward Citations = 1,542

Loading Chart...
Loading Chart...

509 inventors (with patents filed for the assignee):

goldMedal Ian James Collins (20 out of 41 patents)

silverMedal Dan Niculescu-Duvaz (18 out of 26 patents)

bronzeMedal Caroline Joy Springer (18 out of 41 patents)

4.  Julian Blagg (17 out of 19 patents)

5.  Edward McDonald (16 out of 22 patents)

6.  Bernard Thomas Golding (15 out of 30 patents)

7.  Ian Robert Hardcastle (15 out of 16 patents)

8.  Swen Hoelder (15 out of 15 patents)

9.  Allan Michael Jordan (15 out of 23 patents)

10.  Thomas Peter Matthews (14 out of 14 patents)

11.  Ion Niculescu-Duvaz (14 out of 16 patents)

12.  Alfonso Zambon (14 out of 15 patents)

13.  Richard Marais (14 out of 26 patents)

14.  Roger John Griffin (14 out of 20 patents)

15.  Sergio Quezada (13 out of 13 patents)


Core Competencies:
BCL6 Inhibitors
PARG Inhibitory Compounds
Personalized Cancer Treatment
MDM2-P53 Interaction Inhibitors
Anti-CD25 Antibody Agents
RET Kinase Inhibitors
Immunomodulatory Antibodies
Microsatellite Instability Identification
Heat Shock Protein Inhibitors
Treg Depletion Strategies
Cancer Treatment Compounds
Dietary Cancer Therapies

263 patents:

1. 12509457 - Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 (2025-12-30),
2. 12486285 - BCL6 inhibitors (2025-12-02),
3. 12387819 - Enhanced detection of target DNA by fragment size analysis (2025-08-12),
4. 12367980 - Methods for predicting treatment response in cancers (2025-07-22),
5. 12129236 - PARG inhibitory compounds (2024-10-29),
6. 12110286 - Benzimidazolone derived inhibitors of BCL6 (2024-10-08),
7. 12109184 - Personalized methods of treating cancer (2024-10-08),
8. 12077526 - Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them (2024-09-03),
9. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),
10. 12042477 - Dietary product devoid of at least two non essential amino acids (2024-07-23),
11. 11919960 - Anti-CD25 antibody agents (2024-03-05),
12. 11919959 - Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis (2024-03-05),
13. 11897877 - Inhibitor compounds (2024-02-13),
14. 11884671 - Purinone compounds and their use in treating cancer (2024-01-30),
15. 11879014 - Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody (2024-01-23),
Cancer Research Technology Limited is the commercialization and development arm of Cancer Research UK, the world's leading cancer charity. Their mission is to translate cutting-edge cancer research into new therapies and diagnostics to help improve patient outcomes. With a strong focus on collaboration, Cancer Research Technology works with academic institutions, biotechnology companies, and pharmaceutical partners to advance the discovery and development of innovative cancer treatments.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

263 Patents

#19 in London

#59 in United Kingdom

#3,225 in the World

...
London, United Kingdom

Cancer Research Technology Limited

Forward Citations = 1,542

509 inventors:

goldMedal Ian James Collins (20 out of 41 patents)

silverMedal Dan Niculescu-Duvaz (18 out of 26 patents)

bronzeMedal Caroline Joy Springer (18 out of 41 patents)

4.  Julian Blagg (17 out of 19 patents)

5.  Edward McDonald (16 out of 22 patents)

Please report any incorrect information to support@idiyas.com
Loading…